Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP404063.RAVGemhZT6IhKbAOkFxrC9OVU5ZQlqgB7F7OP3Xntl1GM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP404063.RAVGemhZT6IhKbAOkFxrC9OVU5ZQlqgB7F7OP3Xntl1GM130_assertion type Assertion NP404063.RAVGemhZT6IhKbAOkFxrC9OVU5ZQlqgB7F7OP3Xntl1GM130_head.
- NP404063.RAVGemhZT6IhKbAOkFxrC9OVU5ZQlqgB7F7OP3Xntl1GM130_assertion description "[The MEF2A mutations may account for up to 1.93% of the disease population; thus, genetic testing based on mutational analysis of MEF2A may soon be available for many coronary artery disease/myocardial infarction patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP404063.RAVGemhZT6IhKbAOkFxrC9OVU5ZQlqgB7F7OP3Xntl1GM130_provenance.
- NP404063.RAVGemhZT6IhKbAOkFxrC9OVU5ZQlqgB7F7OP3Xntl1GM130_assertion evidence source_evidence_literature NP404063.RAVGemhZT6IhKbAOkFxrC9OVU5ZQlqgB7F7OP3Xntl1GM130_provenance.
- NP404063.RAVGemhZT6IhKbAOkFxrC9OVU5ZQlqgB7F7OP3Xntl1GM130_assertion SIO_000772 15861005 NP404063.RAVGemhZT6IhKbAOkFxrC9OVU5ZQlqgB7F7OP3Xntl1GM130_provenance.
- NP404063.RAVGemhZT6IhKbAOkFxrC9OVU5ZQlqgB7F7OP3Xntl1GM130_assertion wasDerivedFrom befree-20140225 NP404063.RAVGemhZT6IhKbAOkFxrC9OVU5ZQlqgB7F7OP3Xntl1GM130_provenance.
- NP404063.RAVGemhZT6IhKbAOkFxrC9OVU5ZQlqgB7F7OP3Xntl1GM130_assertion wasGeneratedBy ECO_0000203 NP404063.RAVGemhZT6IhKbAOkFxrC9OVU5ZQlqgB7F7OP3Xntl1GM130_provenance.